The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy
Official Title: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
Study ID: NCT06130787
Brief Summary: French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
CHU Annecy-Genevois, Annecy, , France
Institut Bergonié, Bordeaux, , France
CHU Caen, Caen, , France
CHU de Clermont-Ferrand, Clermont-Ferrand, , France
CHU Créteil, Créteil, , France
Centre Hospitalier Emile Roux, Le Puy-en-Velay, , France
CHRU Lille, Lille, , France
CHU Limoges, Limoges, , France
Centre Léon Bérard, Lyon, , France
Institut Paoli-Calmettes, Marseille, , France
CHU Nancy, Nancy, , France
Groupe Hospitalier Paris Saclay - Site de Bicêtre, Paris, , France
CHU Rennes, Rennes, , France
CHU Saint-Etienne, Saint-Étienne, , France
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, , France
CHU Versailles, Versailles, , France
Name: Marc BERGER
Affiliation: University Hospital, Clermont-Ferrand
Role: PRINCIPAL_INVESTIGATOR